--- Connecting LPs & GPs worldwide
--- Connecting LPs & GPs worldwide
Israeli biosurgery company LifeBond has completed its Series C financing round in excess of $20m, led by Giza Venture Capital and Morris Kahn’s Aurum Ventures, with Johnson & Johnson Development Corporation also participating.
Existing investors Pitango Venture Capital, Robert Taub, founder and former CEO of Omrix Biopharmaceuticals, Leon Recanati’s GlenRock Israel, and The Zitelman Group also took part in in this round.
LifeBond develops surgical sealants, glues and hemostats intended for preventing leakage and bleeding. The company said it plans to use the financing to complete the pre-clinical and clinical phases of the company’s flagship sealant.
LifeBond CEO Ishay Attar said, “We greatly value the support of our investors, who represent the premier life science funds in Israel and Europe.
“We are looking forward to using the proceeds provided by this round to bring our first products to market as early as possible.”
In June Giza participated in a $10.5m funding round for Tel Aviv-based software company Soluto. The firm targets seed and early-stage technology companies and currently manages five funds totaling some $600m.
Copyright © 2011 AltAssets
Private equity activity in Israel is reaching new heights. In this IVCJ article, Zeev Holtzman, chairman and founder of Giza Venture Capital, looks at the rapid emergence of the domestic private equity industry.
In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.
Become a Premium SubscriberIf you are already a AltAssets subscriber please log in below.
